CCII 京都大学大学院医学研究科附属 がん免疫総合研究センター

  1. Home
  2. 研究
  3. 研究部門、ラボ & 研究者
  4. 臨床がん免疫薬効薬理部門
  5. 菊池 理 准教授

菊池 理 准教授
臨床がん免疫薬効薬理部門

学歴

  • 1998-2004: 京都大学医学部医学科 卒業
  • 2012-2016: 京都大学大学院医学研究科博士課程　修了

職歴

  • 2004-2006: 財団法人田附興風会医学研究所北野病院　内科研修医
  • 2006-2009: 倉敷中央病院　消化器内科 医員
  • 2009-2012: 倉敷中央病院　消化器内科 医員 スタッフ医師
  • 2016/4-2016/10: 京都大学医学部附属病院　がんセンター　医員
  • 2016-2019: Research Fellow, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
  • 2019/10-2019/12: 京都大学医学部附属病院　腫瘍内科　医員
  • 2020/1-2020/6: 京都大学医学部附属病院　クリニカルバイオリソースセンター　特定助教
  • 2020/7-2023/5: 京都大学医学部附属病院　腫瘍内科　助教
  • 2023/6~: 京都大学大学院医学研究科附属がん免疫総合研究センター　臨床がん免疫薬効薬理部門　准教授

所属学会

主な論文

Nguyen Vu TH, Kikuchi O, Ohashi S, Saito T, Ida T, Nakai Y, Cao Y, Yamamoto Y, Kondo Y, Mitani Y, Kataoka S, Kondo T, Katada C, Yamada A, Matsubara J, Muto M. Combination therapy with WEE1 inhibition and trifluridine/tipiracil against esophageal squamous cell carcinoma. Cancer Sci. 2023 Dec;114(12):4664-4676. https://doi.org/10.1111/cas.15966. Epub 2023 Sep 19. PMID: 37724648; PMCID: PMC10728021.

Jo, N., Hidaka, Y., Kikuchi, O., Fukahori, M., Sawada, T., Aoki, M., Yamamoto, M., Nagao, M., Morita, S., Nakajima, T., Muto, M., & Hamazaki, Y. (2023). Impaired CD4+ T cell response in older adults is associated with reduced immunogenicity and reactogenicity of mRNA COVID-19 vaccination. Nature Aging, 3(1), 82-92. https://doi.org/10.1038/s43587-022-00343-4

Li, T., Kikuchi, O. (Co-corresponding author), Zhou, J., Wang, Y., Pokharel, B., Bastl, K., Gokhale, P., Knott, A., Zhang, Y., Doench, J. G., Ho, Z. V., Catenacci, D. V., & Bass, A. J. (2023). Developing SHP2-based combination therapy for KRAS-amplified cancer. JCI Insight, 8(3), e152714. https://doi.org/10.1172/jci.insight.152714

Abe, T., Horisawa, Y., Kikuchi, O., Ozawa-Umeta, H., Kishimoto, A., Katsuura, Y., Imaizumi, A., Hashimoto, T., Shirakawa, K., Takaori-Kondo, A., Yusa, K., Asakura, T., Kakeya, H., & Kanai, M. (2022). Pharmacologic characterization of TBP1901, a prodrug form of aglycone curcumin, and CRISPR-Cas9 screen for therapeutic targets of aglycone curcumin. Eur J Pharmacol, 935, 175321. https://doi.org/10.1016/j.ejphar.2022.175321

Mitani, Y., Ohashi, S., Kikuchi, O., Nakai, Y., Ida, T., Mizumoto, A., Yamamoto, Y., Saito, T., Kataoka, S., Matsubara, J., Yamada, A., Kanai, M., Matsumoto, S., Sakai, H., Yoshikawa, K., Nakamura, E., & Muto, M. (2022). HER2 G776S mutation promotes oncogenic potential in colorectal cancer cells when accompanied by loss of APC function. Sci Rep, 12(1), 9213. https://doi.org/10.1038/s41598-022-13189-y

Mori, Y., Kikuchi, O., Horimatsu, T., Hara, H., Hironaka, S., Kojima, T., Kato, K., Tsushima, T., Ishihara, R., Mukai, K., Uozumi, R., Tada, H., Kasai, H., Kawaguchi, A., & Muto, M. (2022). Multicenter phase II study of trifluridine/tipiracil for esophageal squamous carcinoma refractory/intolerant to 5-fluorouracil, platinum compounds, and taxanes: the ECTAS study. Esophagus, 19(3), 444-451. https://doi.org/10.1007/s10388-021-00905-2

Ohashi, S., Maruno, T., Fukuyama, K., Kikuchi, O., Sunami, T., Kondo, Y., Imai, S., Matsushima, A., Suzuki, K., Usui, F., Yakami, M., Yamada, A., Isoda, H., Matsumoto, S., Seno, H., Muto, M., & Inoue, M. (2021). Visceral fat obesity is the key risk factor for the development of reflux erosive esophagitis in 40-69-years subjects. Esophagus, 18(4), 889-899. https://doi.org/10.1007/s10388-021-00859-5

Ohashi, S., Kikuchi, O., Nakai, Y., Ida, T., Saito, T., Kondo, Y., Yamamoto, Y., Mitani, Y., Nguyen Vu, T. H., Fukuyama, K., Tsukihara, H., Suzuki, N., & Muto, M. (2020). Synthetic Lethality with Trifluridine/Tipiracil and Checkpoint Kinase 1 Inhibitor for Esophageal Squamous Cell Carcinoma. Mol Cancer Ther, 19(6), 1363-1372. https://doi.org/10.1158/1535-7163.MCT-19-0918

Sethi, N. S., Kikuchi, O., Duronio, G. N., Stachler, M. D., McFarland, J. M., Ferrer-Luna, R., Zhang, Y., Bao, C., Bronson, R., Patil, D., Sanchez-Vega, F., Liu, J. B., Sicinska, E., Lazaro, J. B., Ligon, K. L., Beroukhim, R., & Bass, A. J. (2020). Early TP53 alterations engage environmental exposures to promote gastric premalignancy in an integrative mouse model. Nat Genet, 52(2), 219-230. https://doi.org/10.1038/s41588-019-0574-9

Kijima, T, Nakagawa, H, Shimonosono, M, Chandramouleeswaran, P M, Hara, T, Sahu, V, Kasagi, Y, Kikuchi, O, Tanaka, K, Giroux, V, Muir, A B, Whelan, K A, Ohashi, S, Naganuma, S, Klein-Szanto, A J, Shinden, Y, Sasaki, K, Omoto, I, Kita, Y, Muto, M, Bass, A J, Diehl, J A, Ginsberg, G G, Doki, Y, Mori, M, Uchikado, Y, Arigami, T, Avadhani, N G, Basu, D, Rustgi, A K and Natsugoe, S. Three-Dimensional Organoids Reveal Therapy Resistance of Esophageal and Oropharyngeal Squamous Cell Carcinoma Cells. Cell Mol Gastroenterol Hepatol 2019; 7(1): 73-91.

Mizumoto, A, Ohashi, S, Kamada, M, Saito, T, Nakai, Y, Baba, K, Hirohashi, K, Mitani, Y, Kikuchi, O, Matsubara, J, Yamada, A, Takahashi, T, Lee, H, Okuno, Y, Kanai, M and Muto, M. Combination treatment with highly bioavailable curcumin and NQO1 inhibitor exhibits potent antitumor effects on esophageal squamous cell carcinoma. J Gastroenterol 2019; 54(8): 687-698.

Nagaraja, A. K., Kikuchi, O., & Bass, A. J. (2019). Genomics and Targeted Therapies in Gastroesophageal Adenocarcinoma. Cancer Discov, 9(12), 1656-1672. https://doi.org/10.1158/2159-8290.Cd-19-0487

Sethi, N, Kikuchi, O (Co-corresponding author), McFarland, J, Zhang, Y, Chung, M, Kafker, N, Islam, M, Lampson, B, Chakraborty, A, Kaelin, W G, Jr. and Bass, A J. Mutant p53 induces a hypoxia transcriptional program in gastric and esophageal adenocarcinoma. JCI Insight 2019; 4(15): e128439.

Yoshioka, M, Ohashi, S, Ida, T, Nakai, Y, Kikuchi, O, Amanuma, Y, Matsubara, J, Yamada, A, Miyamoto, S, Natsuizaka, M, Nakagawa, H, Chiba, T, Seno, H and Muto, M. Distinct effects of EGFR inhibitors on epithelial- and mesenchymal-like esophageal squamous cell carcinoma cells. J Exp Clin Cancer Res 2017; 36(1): 101.

Yoshioka, M, Ohashi, S, Ida, T, Nakai, Y, Kikuchi, O, Amanuma, Y, Matsubara, J, Yamada, A, Miyamoto, S, Natsuizaka, M, Nakagawa, H, Chiba, T, Seno, H and Muto, M. Distinct effects of EGFR inhibitors on epithelial- and mesenchymal-like esophageal squamous cell carcinoma cells. J Exp Clin Cancer Res 2017; 36(1): 101.

Kikuchi, O, Ohashi, S, Horibe, T, Kohno, M, Nakai, Y, Miyamoto, S, Chiba, T, Muto, M and Kawakami, K. Novel EGFR-targeted strategy with hybrid peptide against oesophageal squamous cell carcinoma. Sci Rep 2016; 6: 22452.

Kikuchi, O, Ohashi, S, Nakai, Y, Nakagawa, S, Matsuoka, K, Kobunai, T, Takechi, T, Amanuma, Y, Yoshioka, M, Ida, T, Yamamoto, Y, Okuno, Y, Miyamoto, S, Nakagawa, H, Matsubara, K, Chiba, T and Muto, M. Novel 5-fluorouracil-resistant human esophageal squamous cell carcinoma cells with dihydropyrimidine dehydrogenase overexpression. Am J Cancer Res 2015; 5(8): 2431-2440.

Ohashi, S, Miyamoto, S, Kikuchi, O, Goto, T, Amanuma, Y and Muto, M. Recent Advances From Basic and Clinical Studies of Esophageal Squamous Cell Carcinoma. Gastroenterology 2015; 149(7): 1700-1715.

Kikuchi, O, Ezoe, Y, Morita, S, Horimatsu, T and Muto, M. Narrow-band imaging for the head and neck region and the upper gastrointestinal tract. Jpn J Clin Oncol 2013; 43(5): 458-465.

Kikuchi, O, Ezoe, Y, Morita, S, Horimatsu, T and Muto, M. Narrow-band imaging for the head and neck region and the upper gastrointestinal tract. Jpn J Clin Oncol 2013; 43(5): 458-465.

Watanabe, T, Tsuji, Y, Takahashi, N, Yoshida, T, Tamaoki, M, Kikuchi, O, Watanabe, Y, Kodama, Y, Isoda, H, Yamamoto, H and Chiba, T. Relationship between pancreatic perfusion parameters and clinical complications of severe acute pancreatitis. Pancreas 2013; 42(1): 180-182.

Kikuchi, O, Mouri, H, Matsueda, K and Yamamoto, H. Endoscopic Submucosal Dissection for Treatment of Patients Aged 75 Years and over with Esophageal Cancer. ISRN Gastroenterol 2012; 2012: 671324.

Ohara, Y, Kikuchi, O, Goto, T, Yoshida, T, Mori, H, Matsueda, K and Yamamoto, H. Successful treatment of a patient with sepsis and liver abscess caused by Edwardsiella tarda. Internal medicine 2012; 51(19): 2813-2817.

WordPress Lightbox